This database contains 123 studies, archived under the term: "cholinesterase inhibitors"
Click here to filter this large number of results.
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial
Dysken, Maurice W.,
Sano, Mary,
Asthana, Sanjay,
Vertrees, Julia E.,
Pallaki, Muralidhar,
Llorente, Maria,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Zachariah, Sally,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Segal, Yoav,
Peduzzi, Peter N.,
Guarino, Peter D.
Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]
Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire
Carcaillon, L.,
Berrut, G.,
Sellal, F.,
Dartigues, J. F.,
Gillette, S.,
Pere, J. J.,
Bourdeix, I.
Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]